EditorialOpen Access · CC BY-NC 4.0
Safety and efficacy of ibrutinib in a patient with severe renal impairment
Hematology Reports · 2017
DOI: 10.4081/hr.2017.7078 ↗Kurz gefasst
Editorial in der Zeitschrift Hematology Reports, 2017. Verfasst von Kalman Filanovsky und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kaplan Medical Center, Rehovot; Hadassah and Hebrew University Medical School, Jerusalem, Israel. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Not available
Schlagwörter
Stichwörter der Autor:innen
chronic renal failureibrutiniblymphoma
Autor:innen und Institutionen
- Kaplan Medical Center, Rehovot; Hadassah and Hebrew University Medical School, Jerusalem, Israel.
Zitieren
APA
Filanovsky, K., & Shvidel, L. (2017). Safety and efficacy of ibrutinib in a patient with severe renal impairment. Hematology Reports. https://doi.org/10.4081/hr.2017.7078
Vancouver
Filanovsky K, Shvidel L. Safety and efficacy of ibrutinib in a patient with severe renal impairment. Hematology Reports. 2017. doi:10.4081/hr.2017.7078
BibTeX
@article{Filanovsky2017,
author = {Filanovsky, Kalman and Shvidel, Lev},
title = {Safety and efficacy of ibrutinib in a patient with severe renal impairment},
journal = {Hematology Reports},
year = {2017},
doi = {10.4081/hr.2017.7078}
}
EUVIMED